Lan Zhou

Lan Zhou

PhD student at the University of Groningen

Hi there, welcome to my personal page

I am a PhD student in Sommer’s lab at the Department of Biomedical Science and Department of Psychiatry, University Medical Center of Groningen, starting in 2022.

Education Background:

* 2018-2021, MSc from East China Normal University, Shanghai New York University Brain and Cognitive Science Joint Institute.
* 2013-2017, BSc from Shanghai Jiao Tong University

Currently, I am involved in an exciting national-wide clinical trial HAMLETT STUDY in the Netherlands. My PhD research revolves around understanding the influence of childhood adversities on the clinical course, cognition, and brain development of individuals with schizophrenia, mainly supervised by Prof. Dr. Iris Sommer and Dr. Marieke Begemann. I am applying machine learning, neuroimaging, genectics, and gragh-based network analysis in my research. I am also collaborating on large neuroimaging datasets, like ENIGMA, ABCD and ZIB.

Research Keywords: Childhood Adversities, Sczhizophrenia, Developmental Psychopathology, Neuroimaging, Network Neuroscience, Machine Learning

Beyond my academic pursuits, I am deeply committed to addressing gender inequality and advocating for the rights of children and women. In the future, I aspire to conduct research in these areas and establish a nonprofit organization focused on exploring the social, psychological, and structural factors contributing to health disparities. My goal is to identify effective strategies to promote health equity and overall well-being.

In Industy

From 2020 to 2021, I worked as a Medical Affairs Intern at Pfizer for 8 months. During my internship, I provided academic support for antibiotics products, specifically Cefoperazone-Sulbactam and Ceftazidime-Avibactam. Additionally, I assisted to do policy research related to volume-based procurement in China.

From 2017 to 2018, I served as a Medical Affairs Assistant at Chisie pharmaceutical company. I was responsible for Drug Safety of Respiratory & Neonatal drugs, and diligently reported Adverse Events to the Food and Drug Administration (FDA).